Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 4,566,992	$ 5,030
Short term investments	17,297,165
Related party receivable	24,946	9,571
Prepaid expenses and other current assets	1,066,638	58,436
Total Current Assets	22,955,741	73,037
Property and Equipment, net	53,753	10,782
Other Assets
Restricted cash	1,252	26,214
Debt issuance costs, net		28,229
Deposits	9,320	9,320
Total Other Assets	10,572	63,763
Total Assets	23,020,066	147,582
Current Liabilities
Accounts payable	651,917	505,471
Accrued expenses and other payables	503,050	129,208
Accrued interest	25,364	13,763
Notes payable - current portion		66,806
Total Current Liabilities	1,180,331	715,248
Long Term Liabilities
Notes payable - less current portion		658,194
Convertible notes payable		197,099
Stock warrants liability	122,590	92,150
Total Liabilities	1,302,921	1,662,691
Stockholders' Equity (Deficit)
Common stock, $.0002 par value; 50,000,000 shares authorized, 6,375,426 and 2,144,542 shares issued and 6,375,426 and 1,858,971 shares outstanding at December 31, 2013 and 2012, respectively	961	405
Additional paid in capital	34,337,591	4,495,832
Deficit accumulated during the development stage	(12,346,630)	(5,935,282)
Total Stockholders' Equity (Deficit)	21,991,922	(1,438,848)
Non-Controlling Interest	(274,777)	(76,261)
Total Stockholders' Equity (Deficit) - Heat Biologics, Inc.	21,717,145	(1,515,109)
Total Liabilities and Stockholders' Equity (Deficit)	23,020,066	147,582
Series 1 Preferred Stock [Member]
Stockholders' Equity (Deficit)
Series preferred stock		11
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Series preferred stock		$ 186